Progress in Oncology 2001 PDF Download

Author: Vincent T. DeVita
Publisher: Jones & Bartlett Learning
ISBN: 9780763715892
Category : Cancer
Languages : en
Pages : 390

View

Book Description
Medicine

Author: Vincent T. Devita
Publisher: Jones & Bartlett Pub
ISBN: 9780763712082
Category : Medical
Languages : en
Pages : 390

View

Book Description
Buy Progress in Oncology 2002 and 2001 together and save! Each year this volume will highlight progress in the basic and clinical aspects of oncology reviewed by leaders in the field. Comprehensive reviews on important advances in the previous year will be selected to help cancer research scientists and oncologists stay up-to-date with high impact progress across all disciplines in oncology.

Author: National Cancer Institute (U.S.)
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 88

View

Book Description

Author: Vincent T. DeVita
Publisher: Jones & Bartlett Learning
ISBN: 9780763720636
Category : Cancer
Languages : en
Pages : 412

View

Book Description
The second volume in the annual series, Progress In Oncology 2002 highlights progress in the basic and clinical aspects of oncology and is reviewed by leaders in the field. Comprehensive reviews on important advances in the previous year are selected to help cancer research scientists and oncologists stay up-to-date with high impact progress across all disciplines in oncology.

Author: National Cancer Institute (U.S.)
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 14

View

Book Description

Author: Jacques Barbet
Publisher: John Wiley & Sons
ISBN: 1119706866
Category : Medical
Languages : en
Pages : 202

View

Book Description
The combined effects of population growth and aging have led to an increase in the number of cancers. Preventing, diagnosing, treating and curing cancer are therefore, more than ever, imperatives facing medicine – especially to continue the decrease in cancers' mortality rates and to improve the quality of survival. Over time, the “classic” modes of treatment (surgery, external beam radiotherapy, chemotherapy) have become more refined and efficient. From the beginning of this century, new therapeutic options have been developed: targeted cancer therapy, targeted radionuclide therapy and immunologic therapies based on monoclonal antibodies, cellular therapy and vaccinations. Artificial intelligence and machine learning are also being introduced to the field of oncology. Starting with the basic scientific principles relevant to oncology, this book explains and makes these concepts and innovations accessible to a wide audience – especially in the interest of patients. It also contributes to the oncological field of 4P medicine – with 4P standing for predictive, preventive, personalized and participative.

Author: Gabriel N. Hortobagyi
Publisher: Springer Science & Business Media
ISBN: 2817809181
Category : Medical
Languages : en
Pages : 383

View

Book Description
This is the third volume of our series Progress in Anti-Cancer Chemo therapy. Following the strategy of the first two volumes, it covers selected aspects of progress in this fast moving field of Oncology, with contribu tions from some of the world's best known leaders in both basic and clin ical research. This year we focused on seven areas: Three prominent Clinical investigators reviewed conceptual advances in cancer research. Dr Buzdar presented a history and overview of the protection of human subjects who participate in clinical research, and the mechanisms developed to assure the ethical conduct of research on human beings. Frei reviewed an exciting and rapidly moving area of che motherapy of solid tumors, including a cogent discussion of the issues related to dose-intensification. Fisher summarized conceptual advances in our therapeutic approach to breast cancer and the paradigm shifts that lead us to our current management strategies. From this summary he pro jected breast cancer research into the future, a daunting task under any circumstance. Fundamental research in cancer biology has been responsible for our improved understanding of the development and progession of malignant disease. Such understanding will lead to improved diagnosis, therapy, and eventually, prevention. Isaacs reviews the area of hereditary breast cancer, a topic undergoing rapid transformation and with mUltiple impli cations in the daily practice of medicine. Fidler, an international expert in metastasis research reviews the potential utility of angiogenesis inhib itors in research and the therapeutic ramifications.

Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 16

View

Book Description

Author: National Cancer Institute (U.S.)
Publisher:
ISBN:
Category :
Languages : en
Pages :

View

Book Description

Author: David Khayat
Publisher: Springer Science & Business Media
ISBN: 2817809203
Category : Medical
Languages : en
Pages : 260

View

Book Description
This is the fourth volume of our series Progress in Anti-cancer Therapy. For the past four years we have taken the challenge to select each year, some of the most interesting topics on the wide field of oncology. As usual, this volume continues the tradition and covers five cancers (breast, prostate, bladder, lym phoma and ovarian), the role of HIV and HTLV in cancer, as well as some deve lopmental pharmacology and behavioral issues. This year, we have particularly focused our attention on one of the most com mon (although rarely addressed) cancer accounting for more than 315,00 newly diagnosed cases and 41,000 cancer-related deaths annually (Landis SH et al., 1999) : prostate cancer. Five chapters address some of the issues concerning this disease. The chap ter by Schroder describes the hopes and pitfalls of early detection of prostate cancer. It reviews the literature on screening studies that have been performed both in the US and in Europe. These studies suggest that cancer mortality could be reduced by screening for prostate cancer, mostly through PSA testing. However, the effectiveness of early detection still needs to be definitely confir med and ongoing randomized studies are described, the results of which will probably help the medical community determine the worth of PSA-based scree ning for prostate cancer. On the same hand, the paper from von Eschenbach is reviewing the clinical problems that are related this disease.